Source:http://linkedlifedata.com/resource/pubmed/id/11071624
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
10
|
| pubmed:dateCreated |
2000-11-27
|
| pubmed:abstractText |
Carriers of a mutation in the prothrombin (clotting factor II) or factor V gene have a 2- to 4-fold greater risk for venous thromboembolism than subjects without the mutations. Whether both mutations also predispose to recurrent venous thromboembolism is unclear. Outpatients who had a first episode of proven symptomatic deep-vein thrombosis and a long-term follow-up were studied. The outcome measure was the cumulative incidence of confirmed venous thromboembolic complications. Two hundred fifty-one patients were enrolled in the study. Mean duration of follow-up was 8.3 years. The prothrombin gene mutation was demonstrated in 27 patients (prevalence, 10.8%; 95% CI, 6.9 to 14.6), and the factor V gene mutation was demonstrated in 41 patients (prevalence, 16.3%; 95% CI, 11.8 to 20.9). The cumulative incidence of venous thromboembolic complications after 10 years was 61.3% (95% CI, 35.7 to 87.9), and the hazard ratio was 2.4 (95% CI, 1.3 to 4.7; P =.004) in patients with the prothrombin gene mutation); the cumulative incidence of venous thromboembolic complications after 10 years was 55.2% (95% CI, 36.4 to 74.0), and the hazard ratio was 2.4 (95% CI, 1.4 to 4.1; P =.001) in patients with the factor V gene mutation. In comparison, the cumulative incidence of venous thromboembolic complications after 10 years was 23.1% (95% CI, 16.2 to 30.1) in patients without the mutations. Prothrombin and factor V gene mutations occur frequently in patients with venous thrombosis and are associated with an increased risk for recurrent venous thromboembolic complications.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
0006-4971
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
96
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
3329-33
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:11071624-Adult,
pubmed-meshheading:11071624-Aged,
pubmed-meshheading:11071624-Aged, 80 and over,
pubmed-meshheading:11071624-Cohort Studies,
pubmed-meshheading:11071624-Factor V,
pubmed-meshheading:11071624-Female,
pubmed-meshheading:11071624-Follow-Up Studies,
pubmed-meshheading:11071624-Heterozygote,
pubmed-meshheading:11071624-Humans,
pubmed-meshheading:11071624-Male,
pubmed-meshheading:11071624-Middle Aged,
pubmed-meshheading:11071624-Mutation,
pubmed-meshheading:11071624-Prevalence,
pubmed-meshheading:11071624-Prothrombin,
pubmed-meshheading:11071624-Recurrence,
pubmed-meshheading:11071624-Retrospective Studies,
pubmed-meshheading:11071624-Risk Factors,
pubmed-meshheading:11071624-Thromboembolism,
pubmed-meshheading:11071624-Venous Thrombosis
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis.
|
| pubmed:affiliation |
Department of Medical and Surgical Sciences, Second Chair of Internal Medicine, University Hospital of Padua, Italy.
|
| pubmed:publicationType |
Journal Article
|